TSC2 and cancer: Some studies have demonstrated that in TSC2-mutated cancer both combination therapy with PD-1 and CTLA-4 antibodies, as well as monotherapy, can enhance CD8+ T cell infiltration in TSC2-deficient human tumors, with the level of infiltration correlating with treatment response (Liu et al., 2018).